Abstract: Provided is a method for preventing or treating a periodontal disease; or a method for improving oral hygiene, including administering a pharmaceutical composition containing tauroursodeoxycholic acid as an active ingredient.

Abstract: The present application relates to perfume raw materials, perfume delivery systems and consumer products comprising such perfume raw materials and/or such perfume delivery systems, as well as processes for making and using such perfume raw materials, perfume delivery systems and consumer products. Such perfume raw materials and compositions, including the delivery systems, disclosed herein expand the perfume communities' options as such perfume raw materials can provide variations on character and such compositions can provide desired odor profiles.

Abstract: The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.

Abstract: Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 5 to 8 hours or longer, followed by a prolonged release.

Abstract: Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 4 to 6 hours or longer, followed by an ascending release rate.

Abstract: Vesicle compositions are provided that comprise a therapeutic compound. The vesicle compositions may be capable of releasing the therapeutic compound in response to the presence of an external trigger. The vesicle compositions may comprise a plurality of biocompatible vesicles. The biocompatible vesicles may comprise a therapeutic compound for treatment of a patient in need thereof, and one or more cross-linkages between two or more of the biocompatible vesicles, each cross-linkage comprising a chemical sensing moiety and a sensed moiety. In some embodiments, the therapeutic compound may be any compound that provides palliative, curative, or otherwise beneficial effects to a patent.

Abstract: Disclosed are non-aqueous carrier compositions capable of forming a gel structure, having a low molecular mass N-acyl glutamic acid diamide having a straight-chain alkyl group, a low molecular mass N-acyl glutamic acid diamide having a branched-chain alkyl group, at least one gel-promoting solvent, and at least one high molecular mass block copolymer having at least one hard segment and at least one soft segment, and at least one solvent capable of solubilizing the at least one hard segment and/or the at least one soft segment of the block copolymer, at least one oil-soluble polar modified polymer; and at least one solvent capable of solubilizing the at least one oil-soluble polar modified polymer, and optionally at least one active ingredient, wherein the composition has a hardness value ranging from about 30 to about 300 gf, a melting point of about 50° C. or higher, and does not require use of wax as a structuring agent. Methods of making and using the compositions are also disclosed.

Abstract: Methods of preparing a dentifrice comprising polymer matrix film with a low solubility flavorant therein are disclosed. The methods comprise combining a polymer matrix film that are free of a low solubility flavorant with a dentifrice base comprising a low solubility flavorant and maintaining the combined polymer matrix film with the dentifrice base comprising low solubility flavorant for an amount of time sufficient for an amount of a low solubility flavorant to transfer from the dentifrice base comprising low solubility flavorant to the polymer matrix film Products comprising low solubility flavorant-free polymer matrix film in a dentifrice base comprising low solubility flavorant are also disclosed.

Abstract: The present disclosure relates to pharmaceutical compositions for inhalation comprising aclidinium in the form of a dry powder of a pharmaceutically acceptable salt in admixture with a pharmaceutically acceptable dry powder carrier, providing a metered nominal dose of aclidinium equivalent to about 200 micrograms aclidinium bromide.

Abstract: The present invention provides a composition comprising vesicles and encapsulated within the vesicles, nucleic acid comprising less than 1000 nucleotides, wherein the vesicles comprise an amphiphilic block copolymer having a hydrophilic and a hydrophobic block. Methods of forming vesicles and methods of delivering nucleic acid, in particular, iRNA into cells, are also provided.

Abstract: A viscous composition of the present invention comprises specific cellulose fibers (A), (A?) and (A?) which are selected according to uses of a cosmetic composition, a gel-like composition and a spray composition. By using the composition of the present invention, a cosmetic composition which is excellent in shape retention ability and dispersion stability and excellent in water tolerance to satisfy the properties and the performance which is necessary for cosmetics; a gel-like composition wherein gel-state can be kept without separation or water release; and a spray composition wherein various functional additives which is necessary for the use is mixed without any problem can be obtained.

Abstract: The invention provides disintegratable adhesive films containing a mixture of high molecular weight and low molecular weight water soluble components; and a pharmaceutically or cosmetically active ingredient. Optionally, the films contain a starch component, a polysaccharide component, a filler, a plasticizer and/or humectant. The films are preferably in the form of an adhesive layer having a thickness sufficient to disintegrate, when exposed to a moist environment and/or a trigger compound, and release the active ingredient. The films can be cut to any desired size or shape to provide conveniently useable unit dosage forms for administration to wet or moist body surfaces for human, pharmaceutical, cosmetic, or veterinary applications. The invention further provides various end uses and methods of administering the film compositions.

Abstract: The method for cleaning dental plaque biofilm from the teeth includes the steps of applying a liquid gellable composition to the teeth, the composition including a positively charged polymer such as chitosan, the liquid composition having a viscosity which results in coverage of substantially all of the exposed areas of the teeth. The liquid composition is then gelled by the addition of a second composition, such as a negatively charged compound. The resulting gelled composition has an adherence to the plaque biofilm which is greater than the adherence between the biofilm and the teeth. The gel layer with the biofilm is peeled off of the teeth, removing the dental plaque.

Abstract: Chewable sustained release compositions and their methods of production are provided. The sustained release compositions contain amphipathic lipids, which are used to encapsulate various drugs and active ingredients.

Abstract: Here described are compounds of formula I: wherein R1 and R2 is independently selected from a group consisting of C10 to C18 alkyl, C12 to C18 alkenyl, and oleyl group; wherein R3 and R4 are independently selected from a group consisting of C1 to C6 alkyl, and C2 to C6 alkanol; wherein X is selected from a group consisting of —CH2—, —S—, and —O— or absent; wherein Y is selected from —(CH2)n, —S(CH2)n, —O(CH2)n—, thiophene, —SO2(CH2)n—, and ester, wherein n=1-4; wherein a=1-4; wherein b=1-4; wherein c=1-4; and wherein Z is a counterion; as well as compositions and pharmaceutical formulations including compounds of formula I which are useful for the delivery of therapeutic agents; and methods of using these compositions and formulations.

Abstract: The compound N-(4-{[4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl]oxy}butyl)octadecanamide is a useful drug compound for enhancing immune response and can be used, for example, as a vaccine adjuvant and a cancer treatment.

Abstract: A method of treating a human subject in need of melatonin therapy comprises administering to a human subject a composition comprising melatonin dispersed in a polymer matrix adapted to cover the melatonin in a melatonin solubility enhancing pH environment after ingestion and to maintain the melatonin solubility enhancing pH environment when said composition is present in said subject's intestines so that an effective amount of melatonin is released into the subject's intestines.

Abstract: In one embodiment, a disinfectant composition includes a peroxide, a peracid, an anionic surfactant, a nonionic polymer, and one or both of a linear fatty alcohol and an alkyl pyrrolidone. The disinfectants provide greater killing rates for microbial populations in short periods of time, and therefore can be considered to be fast-acting disinfectants.

Abstract: A dental material composed of hydrophilic polycaprolactone formed by the process of exposing a hydrophobic caprolactone to ionizing irradiation from a radiation source selected from the group consisting of an Electron Acceleration (E beam), Gamma II, Cobolt, X-ray or a source of UV radiation to form a cross linked polycaprolactone composition consisting of two distinct phases one of which is soluble and the other non-soluble, and adjusting the duration of ionizing radiation and/or the intensity of the radiation to cause the concentration of the soluble phase to be above at least about 65% by weight of the cured polymeric composition whereby the hydrophobic caprolactone becomes hydrophilic.

Abstract: siRNA-conjugated liposomes and micelles, methods of making such conjugates, and methods of using such conjugates, such as for the delivery of siRNA to cells to reduce expression of target polypeptides in such cells, are described.